Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
69
datasets available to search
ShareScore release 0.9.0
Dataset results
69 results for “pediatric epilepsy”
Dataset of EEG recordings of pediatric patients with epilepsy based on the 10-20 system
Open the record for dataset details and reuse information.
Study in Pediatric Subjects With Epilepsy
ClinicalTrials.gov study NCT01494584. IPD Sharing: Not stated. Countries: 1. Publications: 1.
The Prevalence and Risk Factors of Coagulopathy in Pediatric Epilepsy Surgery Patients
ClinicalTrials.gov study NCT05675254. IPD Sharing: NO. Countries: 1. Publications: 1.
Open-label Long-term Study of Adjunctive Brivaracetam in Pediatric Subjects With Epilepsy
ClinicalTrials.gov study NCT01364597. IPD Sharing: Not stated. Countries: 12. Publications: 3.
Transcutaneous Auricular Vagus Nerve Stimulation for Pediatric Epilepsy
ClinicalTrials.gov study NCT02004340. IPD Sharing: Not stated. Countries: 1. Publications: 1.
The Potential of a Low Glutamate Diet as a Treatment for Pediatric Epilepsy
ClinicalTrials.gov study NCT04545346. IPD Sharing: NO. Countries: 1. Publications: 1.
Determinants of Adaptive Behavior Through the Vineland Scale in Pediatric Patients with Severe and Drug-resistant Epilepsy
ClinicalTrials.gov study NCT06832020. IPD Sharing: YES. Countries: 1. Publications: 8.
Epidiolex® for Anxiety in Pediatric Epilepsy
ClinicalTrials.gov study NCT05324449. IPD Sharing: NO. Countries: 1. Publications: 1.
Transition From Pediatric to Adult Epilepsy Care
ClinicalTrials.gov study NCT06778772. IPD Sharing: Not stated. Countries: 1. Publications: 2.
Voronistat in Pediatric Patients With Drug Resistant Epilepsy
ClinicalTrials.gov study NCT03894826. IPD Sharing: NO. Countries: 1. Publications: 2.
Supporting Treatment Adherence Regimens in Pediatric Epilepsy: The STAR Trial
ClinicalTrials.gov study NCT01851057. IPD Sharing: NO. Countries: 1. Publications: 2.
Cannabidiol (CBD) and Pediatric Epilepsy
ClinicalTrials.gov study NCT02447198. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Sleep Intervention for Pediatric Epilepsy
ClinicalTrials.gov study NCT02514291. IPD Sharing: NO. Countries: 1. Publications: 2.
Use of a Tonometer to Identify Epileptogenic Lesions During Pediatric Epilepsy Surgery
ClinicalTrials.gov study NCT04344626. IPD Sharing: NO. Countries: 2. Publications: 16.
Ketogenic Diet in Pediatric Intractable Epilepsy
ClinicalTrials.gov study NCT06310954. IPD Sharing: NO. Countries: 1. Publications: 5.
Seizure outcome of pediatric epilepsy surgery: systematic review and meta-analyses
<p><b>Objective:</b> This systematic review and meta-analyses assessed seizure outcome following pediatric epilepsy surgery.</p> <p><b>Methods: </b>MEDLINE, Embase and Cochrane were searched for pediatric epilepsy surgery original research from 1990 to 2017. The outcome was seizure freedom at 12 months or longer follow-up. Using random effects models, the effect sizes for controlled studies, uncontrolled studies on surgery locations (temporal lobe [TL], extra-temporal lobe [ETL] or hemispheric surgery), pathologies, non-lesional epilepsy and incomplete resection were estimated. Meta-regression assessed the relationship between age at surgery, age at seizure onset and seizure outcome. Random-effects network meta-analysis was conducted for surgery locations.</p> <p><b>Results:</b> 258 studies were included. Surgery achieved higher seizure freedom than medical therapy (OR=6.49 [95%CI: 2.87, 14.70], p<0.001). Seizure freedom declined over time after surgery, from 64.8% (95%CI: 51.2%, 76.4%; p=0.034) at 1 year, to 60.3% (95%CI: 52.9%, 67.4%; p=0.007) at 5 years, and 39.7% (95%CI: 28.4%, 52.2%, p=0.106) at 10 years. Seizure freedom was (i) highest for hemispheric surgery, followed by TL, and ETL surgery; and (ii) highest for tumor, and lower for malformations of cortical development. Seizure freedom was lower for non-lesional than lesional epilepsy (OR=0.54 [95%CI: 0.34, 0.88], p=0.013), and incomplete than complete resection (OR=0.13 [95%CI: 0.08, 0.21], p<0.001). Age at surgery and age at seizure onset were associated with seizure freedom for mixed pathologies and surgery locations, and TL surgery.</p> <p><b>Conclusion:</b> Epilepsy surgery was more effective than medical therapy to control seizures. Understanding seizure outcomes of different surgery locations, pathologies, non-lesional epilepsy and incomplete resection will assist with pre-surgical counselling.</p>
VNS and seizure outcomes in pediatric refractory epilepsy: Systematic review and meta-analysis
<p>This data provides supplemental information for the systematic review and Meta-analysis. Supplemental tables report the detailed serach strategy (Supplementary Table <span><span><span><span><span><span><span><span><span>1), details of included studies (</span></span></span></span></span></span></span></span></span>Supplementary Table <span><span><span><span><span><span><span><span><span>2), list of excluded studies (</span></span></span></span></span></span></span></span></span>Supplementary Table <span><span><span><span><span><span><span><span><span>3), 50% Responder Rate in children with Lennox-Gastaut syndrome after VNS insertion (</span></span></span></span></span></span></span></span></span>Supplementary Table <span><span><span><span><span><span><span><span><span>4), 50% Responder Rate in children with Dravet syndrome after VNS insertion (</span></span></span></span></span></span></span></span></span>Supplementary Table 5<span><span><span><span><span><span><span><span><span>), VNS settings and other seizure outcomes reported in the included studies (</span></span></span></span></span></span></span></span></span>Supplementary Table 6<span><span><span><span><span><span><span><span><span>) and Studies reporting a formal Quality of life (QOL) assessment in children post VNS implantation (</span></span></span></span></span></span></span></span></span>Supplementary Table 7<span><span><span><span><span><span><span><span><span>). </span></span></span></span></span></span></span></span></span></p> <p><b>Supplemental figure 1 </b><strong>(S1)</strong> shows the PRISMA flowchart for this systematic review. </p> <p><strong>Supplemental Figure 2</strong><span><span><span><span><span><span><span><span><span> <strong>(S2)</strong>: </span></span></span></span></span></span></span></span></span><span><span><span><span><span><span><span><span><span>Determinants of Seizure Outcomes. Multivariable regression showed 50%-RR at last reported follow-up to increase with increasing age of onset of seizures and decrease with the number of ASMs tried before VNS implantation (A). Higher 50%-RR 1-year after VNS implantation was seen in patients with shorter duration of epilepsy and fewer number of ASM trials (B). Decline in 50%-RR at 1 and 2 year follow-up in studies with a higher proportion of males (C). Proportion of seizure free patients at last reported follow-up also decreases with a greater number of ASM trials before VNS implantation (D). [50%-RR: 50% Responder Rate, ASM: Anti-seizure Medication, VNS: Vagus Nerve Stimulator; Bubbles represent individual effect size for studies, lines represent ordinary least squares regression models, and<a name="_Hlk61802391"> </a>the shading represents 95% confidence regions.</span></span></span></span></span></span></span></span></span></p> <p><strong>Supplemental figure 3 (S3)</strong>: <span>Forest plots for proportion of seizure free patients. </span><span><span><span><span><span><span><span><span><span>Forest plots for proportion of patients with 50% responder rate at 6 months (B), 1 year (C) and 2 years (D) follow-up summarizing the pooled effect estimate and heterogeneity. </span></span></span></span></span></span></span></span></span></p> <p><strong>Supplemental figure 4 (S4)</strong>: <span>Forest plots for proportion of seizure free patients. </span><span><span><span><span><span><span><span><span><span>Forest plots for proportion of seizure free patients at 6 months (B), 1 year (C) and 2 years (D) follow-up summarizing the pooled effect estimate and heterogeneity.</span></span></span></span></span></span></span></span></span></p>
High Frequency Oscillation in Pediatric Epilepsy Surgery
ClinicalTrials.gov study NCT03790280. IPD Sharing: UNDECIDED. Countries: 1. Publications: 0.
Open-Label PoC Trial of Ganaxolone in Children With PCDH19 Female Pediatric Epilepsy and Other Rare Genetic Epilepsies
ClinicalTrials.gov study NCT02358538. IPD Sharing: NO. Countries: 2. Publications: 0.
Pharmacokinetic Study With an Oral Suspension of Perampanel as Adjunctive Therapy in Pediatric Subjects With Epilepsy
ClinicalTrials.gov study NCT02914314. IPD Sharing: Not stated. Countries: 2. Publications: 0.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.